The Inside Story Of How SoftBank-Backed Zymergen Imploded Four Months After Its $3 Billion IPO Zymergen raised $500 million when it went public in April, on top of more than $1 billion in venture funding. By August, its CEO was out and the synthetic biology company wouldn’t say when it might have commercial revenue. Here’s what went wrong.